Loading…
← CockpitCompetitor Analysis › CCCC C4 Therapeutics, Inc.Open in the cockpit ↗

C4 Therapeutics, Inc.CCCCCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum laggard 15
Mkt cap
$325M
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$9.30M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-121.2 pp
WACC 18.0%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$2.48
1D-2.2%
1W-14.4%
1M-21.7%
3M-38.6%
6M-24.5%
YTD+29.6%
1Y-1.0%
ATR %9.0%
Beta1.66
52w lowhigh52.1% off high

What C4 Therapeutics does

Employees: 104

C4 Therapeutics at a glance

Size C4 Therapeutics (CCCC) is a United States Health Care company (Biotechnology) with a market value of $325M, the 3013th largest of 3,085 United States companies the cockpit tracks. Shares closed at $2.48 on 18 Nov 2026.

Performance Over six months the shares fell 24.5%, against -31.0% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 20 in its peer set.

Growth Revenue grew 7.2% over the last twelve months (peer median +5.8%); the operating margin is -315.9% (peer median -115.0%).

Valuation It trades at 5.4× enterprise value to sales against a peer median of 7.4× (8th cheapest of 15).

Capital Return on invested capital runs 121.2 points below its cost of capital (18.0% WACC).

Short interest Short interest is 35.5% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026CCCC 70Peer median 69
Six months, rebased to 100: C4 Therapeutics against the median of its 20 peers (local-currency closes).

C4 Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$32.3M$35.9M$35.6M$20.8M$31.1M
Revenue growth—+1%+71%-33%—
Gross profit$25.1M$28.0M$27.7M$13.0M$23.5M
EBITDA-$94.8M-$96.5M-$109M-$131M-$122M
Net income-$91.1M-$105M-$105M-$132M-$128M
Free cash flow-$79.7M-$99.3M-$65.3M-$109M-$111M
Capital expenditure$112,000$607,000$180,000$1.71M$5.50M
Total debt$55.2M$60.0M$65.8M$71.0M$87.2M

Quarterly statements and history in the cockpit →

C4 Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-25%0%+25%2105694576303880PROKLRMR358570NAUTLYEL48941873GLSI086900GALTCRMDCTNM476060CCCC6-month return →1-month return →
Up and to the right = strong over both horizons. C4 Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×5,000×10,000×15,000×76303880PROK358570LYEL4894XFOR476060CCCCRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. C4 Therapeutics is the large dot.

C4 Therapeutics competitors and peer comparison

How C4 Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

C4 Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureCCCCPeer medianRank in peer set
1-month return-21.7%-4.7%5th lowest of 20
6-month return-24.5%-31.0%9th highest of 20
Distance from 52-week high-52.1%-54.6%10th highest of 20
Revenue growth (TTM)+7.2%+5.8%7th highest of 13
Operating margin-315.9%-115.0%7th lowest of 15
EV / Sales5.4×7.4×8th cheapest of 15
ROIC minus cost of capital-121.2 pp-22.1 pp2nd lowest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%9.5×n/an/a
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
ProKidney PROKUnited States$314M-38%+4%-24,830%1,625.4×n/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%588.9×n/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
Cuorips 4894.TJapan$309M-10%-80%-1,765%602.9×n/an/a
X4 Pharmaceuticals XFORUnited States$304M-21%-50%-474%11.4×n/an/a
Viva Biotech 1873.HKHong Kong$303M-18%+7%10%1.0×2.6%+19.1%
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Greenwich LifeSciences GLSIUnited States$302M-25%n/an/an/an/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
Galectin Therapeutics GALTUnited States$301M+35%n/an/an/an/an/a
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a

Questions

Which companies are C4 Therapeutics's closest peers?
The cockpit's peer set: Laekna (2105.HK), AP Biosciences (6945.TWO), IMPACT Therapeutics (7630.HK), Medtide (3880.HK), ProKidney (PROK), Larimar Therapeutics (LRMR), GI Innovation (358570.KS), Nautilus Biotechnolgy (NAUT).
Is C4 Therapeutics expensive compared with its peers?
On ev / sales it trades at 5.4× against a peer median of 7.4×, 8th cheapest of 15 in its peer set.
How has C4 Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -24.5% against -31.0% for the median peer; over one year -1.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.